Thyrotropin-secreting pituitary tumors: Clinical presentation, investigation, and management

Current Opinion in Endocrinology and Diabetes

Volumn 8, Issue 5, 2001, Pages 253-258

  Smallridge, R C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CYCLIN D1; OCTREOTIDE; PROTEIN G; PROTEIN P16; PROTEIN P53; PROTIRELIN; SOMATOSTATIN DERIVATIVE; THYROTROPIN;

ADENOMA; CANCER RADIOTHERAPY; CANCER SURGERY; CPG ISLAND; FREE THYROXINE INDEX; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HYPOPHYSIS TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; THYROID HORMONE RESISTANCE; THYROTROPIN RELEASE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 0034808598     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200110000-00005     Document Type: Review

References (62)

1. Syndrome of resistance to thyroid hormone: Insights into thyroid hormone action
2. Syndromes of thyroid hormone resistance due to mutations in the T3β receptor: Progress in our understanding
3. Resistance to thyroid hormone in the absence of mutations in the thyroid hormone receptor genes
4. Thyrotropin-secreting pituitary tumors
5. Pituitary adenomas treated by microsurgery with or without Gamma Knife surgery: Experience in 122 cases
6. Complications of transsphenoidal surgery: The Wellington experience
7. Pituitary adenomas: Results of 684 surgically treated patients and review of the literature
8. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma
9. Thyrotropin-secreting pituitary tumors: Diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National institutes of Health
10. Thyrotropin-secreting pituitary tumors
11. Thyrotropin-secreting tumors
12. Thyrotrophinomas
13. Thyrotropin- and gonadotropin-producing tumors
14. Corticotropin- and Thyrotropin secreting pituitary microadenomas: Detection by dynamic magnetic resonance imaging
15. Is monoclonality in pituitary adenomas synonymous with neoplasia?
16. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker
17. Tumor suppressor genes in pituitary tumor formation
18. Screening of candidate oncogenes in human thyrotroph tumors: Absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes
19. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas
20. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis
21. New pituitary oncogenes
22. Molecular basis of pituitary oncogenesis
23. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: Relation to tumor behavior
24. Methylation mechanisms in pituitary tumorigenesis
25. Molecular pathogenesis of pituitary tumors
26. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications
27. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island
28. Multiple endocrine neoplasia type 1: Clinical and genetic topics
29. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: Analysis of 20 Japanese sporadic cases with MEN1
30. Thyrotropinomas in multiple endocrine neoplasia type 1 (MEN-l)
31. Screening for MEN1 tumor suppressor gene mutations in sporadic pituitary tumors
32. Treatment of a thyrotropinoma with octreotide-LAR in a patient with multiple endocrine neoplasia-1
33. p53 Expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions
34. Mdm2 and the p53 pathway in human pituitary adenomas
35. The expression of thyrotrophin-releasing hormone receptor 1 messenger ribonucleic acid in human pituitary adenomas
36. An abnormality of thyroid hormone receptor expression may explain abnormal thyrotropin production in thyrotropin-secreting pituitary tumors
37. Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas
38. Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: Relation to pituitary tumor
39. Angiogenesis in pituitary adenomas - Relation to endocrine function, treatment and outcome
40. Role of matrix metalloproteinase 9 in pituitary tumor behavior
41. Angiogenesis in pituitary adenomas and the normal pituitary gland
42. The efficacy of conventional radiation therapy in the management of pituitary adenoma
43. Gamma Knife radiosurgery for functioning pituitary adenomas
44. Gamma Knife radiosurgery for functioning pituitary microadenoma
45. Gamma Knife radiosurgery for pituitary adenomas
46. Gamma Knife radiosurgery for pituitary tumors
47. Stereotactic conformal radiotherapy for pituitary adenomas: Technique and preliminary experience
48. The future of somatostatin analogue therapy
49. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients
50. Effect of octreotide acetate on thyrotropin-secreting adenoma: Report of two cases and review of the literature
51. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas
52. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide
53. Thyrotropin-secreting pituitary adenoma responsive to bromocriptine therapy
54. Gene therapy for pituitary tumors
55. Targeted expression of toxic genes directed by pituitary hormone promoters: A potential strategy for adenovirus-mediated gene therapy of pituitary tumors
56. Recent developments in gene therapy: Applications for the treatment of pituitary tumors
57. Primary hypothyroidism presenting as a pituitary mass
58. Residual pituitary enlargement in primary hypothyroidism despite 1 1/2 years of L-thyroxine therapy
59. MR imaging of pituitary hyperplasia in a child with growth arrest and primary hypothyroidism
60. Transdifferentiation of somatotrophs to thyrotrophs in the pituitary of patients with protracted primary hypothyroidism
61. Reversible pituitary enlargement in the syndrome of resistance to thyroid hormone
62. A pituitary tumor in a patient with thyroid hormone resistance: A diagnostic dilemma